Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
18.44
+0.58 (3.25%)
Nov 21, 2024, 1:54 PM EST - Market open

Company Description

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases.

Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

The company’s clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.

It has a cooperative research and development agreement with National Institutes of Health’s National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome.

The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.

Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Travere Therapeutics, Inc.
Travere Therapeutics logo
Country United States
Founded 2008
Industry Biotechnology
Sector Healthcare
Employees 380
CEO Eric Dube

Contact Details

Address:
3611 Valley Centre Drive, Suite 300
San Diego, California 92130
United States
Phone 888 969 7879
Website travere.com

Stock Details

Ticker Symbol TVTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001438533
CUSIP Number 89422G107
ISIN Number US89422G1076
Employer ID 26-2383102
SIC Code 2834

Key Executives

Name Position
Dr. Eric M. Dube Ph.D. President, Chief Executive Officer and Director
Christopher Cline C.F.A. Chief Financial Officer
Elizabeth E. Reed J.D. Senior Vice President, General Counsel and Corporate Secretary
Dr. William E. Rote Ph.D. Senior Vice President and Head of Research and Development
Peter Heerma Chief Commercial Officer
Sandra Calvin SVice President, Corporate Controller and Chief Accounting Officer
Nivi Nehra Vice President of Corporate Communications and Investor Relations
Angela Giannantonio Senior Vice President of Human Resources
Casey Logan Chief Business Officer
Dr. Jula Inrig M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 8-K Current Report
Nov 8, 2024 424B5 Filing
Nov 7, 2024 424B5 Filing
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 31, 2024 424B5 Filing